Pre-made Lintuzumab benchmark antibody ( Whole mAb Radiolabelled, anti-CD33 therapeutic antibody, Anti-p67/SIGLEC3/SIGLEC-3 Antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Lintuzumab biosimilar, Whole mAb Radiolabelled, Anti-CD33 Antibody: Anti-p67/SIGLEC3/SIGLEC-3 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Lintuzumab (SGN-33) is a humanized monoclonal antibody used in the treatment of cancer. The drug had been developed by Seattle Genetics as a treatment for acute myeloid leukemia (AML), a condition which results in the deaths of 9,000 people a year in the United States. Lintuzumab targets the CD33 protein, which is expressed in AML and other myeloproliferative diseases, but does not appear in abundance on normal cells.
| Products Name (INN Index) | Pre-Made Lintuzumab biosimilar, Whole mAb Radiolabelled, Anti-CD33 Antibody: Anti-p67/SIGLEC3/SIGLEC-3 therapeutic antibody |
|---|---|
| INN Name | Lintuzumab |
| Target | CD33 |
| Format | Whole mAb Radiolabelled |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Discontinued |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 1996 |
| Year Recommended | 1997 |
| Companies | PDL BioPharma,Seattle Genetics |
| Conditions Approved | NA |
| Conditions Active | NA |
| Conditions Discontinued | Acute myeloid leukaemia,Myelodysplastic syndromes |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | CD33 |
| Package |
